Cellect to Present Its Breakthrough Stem Cell Production Technology at the BIO-Europe
TEL AVIV, Israel, Nov. 1, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP) , a developer of a novel stem cell production technology, announced today its CEO Dr. Shai Yarkoni will present at the 24th Annual Bio Europe Conference which is being held in Copenhagen, Denmark from November 5-7, 2018. Dr. Yarkoni will present as part of the Cell and Gene Therapies track on Tuesday, November 6 at 10:15 am.
The 24th Annual BIO-Europe conference is Europe's largest partnering conference serving the global biotechnology industry. This year´s BIO-Europe partnering event is expected to draw over 4,000 industry attendees from over 60 countries, representing more than 2,100 companies for three days of high level networking.
"Our ApoGraft™ technology is designed to enable stem cell companies around the world to manufacture and perform safer and more cost effective stem cell-based therapeutics. We believe our technology represents a breakthrough in meeting the rapidly growing demand for stem cells as a raw material. We look forward to meeting with other stem cell leaders with a view towards collaboration and commercialization," stated Cellect CEO Dr. Shai Yarkoni.
About Cellect Biotechnology Ltd.
Cellect Biotechnology (NASDAQ: APOP) has developed a breakthrough technology for the selection of stem cells from any given tissue that aims to improve a variety of stem cell-based therapies.
The Company's technology is expected to provide research, hospitals and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.
Forward Looking Statements
This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; and the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products.. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission ("SEC"), which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.
SOURCE Cellect Biotechnology Ltd.
Company Codes: NASDAQ-SMALL:APOP, TelAviv:APOP